Pharmacoeconomics of linezolid (Q34765976)

4 August 2017

1 reference

title

Pharmacoeconomics of linezolid (English)

1 reference

4 August 2017

1 reference

Santiago Grau

1

1 reference

PubMed ID

18377341

4 August 2017

Carlos Rubio-Terrés

series ordinal

2

1 reference

PubMed ID

18377341

4 August 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

Expert Opinion on Pharmacotherapy

4 August 2017

1 reference

4 August 2017

9

1 reference

4 August 2017

6

1 reference

4 August 2017

987-1000

1 reference

Gram-positive resistance: pathogens, implications, and treatment options: insights from the Society of Infectious Diseases Pharmacists

4 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Modeling transmission of methicillin-resistant Staphylococcus aureus among patients admitted to a hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Methicillin-resistant Staphylococcus aureus bacteraemia diagnosed at hospital admission: distinguishing between community-acquired versus healthcare-associated strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Methicillin-resistant Staphylococcus aureus disease in three communities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Epidemiology and economic impact of meticillin-resistant Staphylococcus aureus: review and analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Epidemiology of staphylococcal resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Cost effect of managing methicillin-resistant Staphylococcus aureus in a long-term care facility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Antimicrobial resistance: cost and containment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Health and economic outcomes of vancomycin-resistant enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Linezolid eradicates MRSA better than vancomycin from surgical-site infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Effect of Linezolid versus Vancomycin on Length of Hospital Stay in Patients with Complicated Skin and Soft Tissue Infections Caused by Known or Suspected Methicillin-Resistant Staphylococci: Results from a Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: results from a multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Cost analysis of switching from i.v. vancomycin to p.o. linezolid for the management of methicillin-resistant Staphylococcus species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Linezolid versus vancomycin for prosthetic joint infections: a cost analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Pharmacoeconomic evaluation of linezolid versus teicoplanin in bacteremia by Gram-positive microorganisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Linezolid: effectiveness and safety for approved and off-label indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

Economic impact and formulary positioning of linezolid: a new anti-Gram-positive antimicrobial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.987

21 January 2018

Identifiers

DOI

10.1517/14656566.9.6.987

1 reference

4 August 2017

1 reference

PubMed ID

18377341